Validation Data Gallery
Filter:
Tested Applications
| Positive WB detected in | HeLa cells, HepG2 cells, MCF-7 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:8000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| WB | See 7 publications below |
Product Information
29450-1-AP targets BRCA2 in WB, ELISA applications and shows reactivity with Human samples.
| Tested Reactivity | Human |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | BRCA2 fusion protein Ag31064 相同性解析による交差性が予測される生物種 |
| Full Name | breast cancer 2, early onset |
| Calculated molecular weight | 384 kDa |
| Observed molecular weight | 384 kDa |
| GenBank accession number | NM_000059 |
| Gene Symbol | BRCA2 |
| Gene ID (NCBI) | 675 |
| RRID | AB_2918309 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P51587 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol , pH 7.3 |
| Storage Conditions | Store at -20°C. Aliquoting is unnecessary for -20oC storage. |
Background Information
BRCA2, also named as FACD and FANCD1, is involved in double-strand break repair and/or homologous recombination. BRCA2 may participate in S phase checkpoint activation. Defects in BRCA2 are a cause of genetic susceptibility to breast cancer (BC) which also called susceptibility to familial breast-ovarian cancer type 2 (BROVCA2).
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for BRCA2 antibody 29450-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Int J Mol Sci CSB Regulates Pathway Choice in Response to DNA Replication Stress Induced by Camptothecin | ||
Aging (Albany NY) A prognostic risk model for programmed cell death and revealing TRIB3 as a promising apoptosis suppressor in renal cell carcinoma | ||
Nucleic Acids Res CSB and SMARCAL1 compete for RPA32 at stalled forks and differentially control the fate of stalled forks in BRCA2-deficient cells | ||
J Enzyme Inhib Med Chem Design, synthesis, and evaluation of novel stilbene derivatives that degrade acidic nucleoplasmic DNA-binding protein 1 (And1) and synergize with PARP1 inhibitor in NSCLC cells | ||
Oncol Lett Olaparib promotes FABP4 expression and reduces antitumor effect in ovarian cancer cells with a BRCA1 mutation | ||
Prostate Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH |